Alterations in energy balance following exenatide administration.

Bradley DP, Kulstad R, Racine N, Shenker Y, Meredith M, Schoeller DA

Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme26 Jun 2012Cited by 39 (Europe PMC)

PMID22735035PMCIDPMC3623676DOI10.1139/h2012-068PepBankPUB-22735035

Source link PubMedAsk about this study

Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanNon-randomized trialEfficacy outcome
In obese participants who completed treatment, body weight fell during exenatide administration.
In plain wordsIn obese participants who completed treatment, body weight fell during exenatide treatment.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseBody weight
Study
n = 18
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · injection · 84 ± 5 daysAs given in this study (human).
Measurements
Weight loss
2 kg
completed subjects
Source sentences
Summary
The average weight loss from the beginning of injection period to the end of the study in completed subjects was 2.0 ± 2.8 kg (p = 0.01).
1 context sentence(design, population, supporting numbers)
Summary · context
After exclusion criteria application, 28 subjects entered into the study and 18 subjects (12 female, 6 male) completed the study, which consisted of 6 visits over 14 weeks and injection of exenatide for an average of 84 ± 5 days.
Report a problemFND-2273503501
02HumanNon-randomized trialEfficacy outcome
In obese participants, fat mass declined during exenatide administration.
In plain wordsIn obese participants, body fat fell during exenatide treatment.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseFat mass
Study
n = 18
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · injection · 84 ± 5 daysAs given in this study (human).
Measurements
Fat mass decline
1.3 kg
exenatide
Source sentences
Summary
Fat mass declined by 1.3 ± 1.8 kg (p = 0.01) while the fat-free mass trended downward but was not significant (0.8 ± 2.2 kg, p = 0.14).
1 context sentence(design, population, supporting numbers)
Summary · context
After exclusion criteria application, 28 subjects entered into the study and 18 subjects (12 female, 6 male) completed the study, which consisted of 6 visits over 14 weeks and injection of exenatide for an average of 84 ± 5 days.
Report a problemFND-2273503502
03HumanNon-randomized trialEfficacy outcome
In obese participants, fat-free mass did not decline significantly during exenatide administration.
In plain wordsIn obese participants, fat-free mass did not fall significantly during exenatide treatment.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeFat-free mass
Study
n = 18
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · injection · 84 ± 5 daysAs given in this study (human).
Measurements
Fat-free mass decline
0.8 kg
exenatide
Source sentences
Summary
Fat mass declined by 1.3 ± 1.8 kg (p = 0.01) while the fat-free mass trended downward but was not significant (0.8 ± 2.2 kg, p = 0.14).
1 context sentence(design, population, supporting numbers)
Summary · context
After exclusion criteria application, 28 subjects entered into the study and 18 subjects (12 female, 6 male) completed the study, which consisted of 6 visits over 14 weeks and injection of exenatide for an average of 84 ± 5 days.
Report a problemFND-2273503503
04HumanNon-randomized trialEfficacy outcome
In obese participants, weight-adjusted total energy expenditure did not change during exenatide administration.
In plain wordsIn obese participants, energy expenditure adjusted for weight did not change during exenatide treatment.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeWeight-adjusted total energy expenditure
Study
n = 18
Outcome group
Energy expenditure and thermogenesis · Metabolic and weight
Studied dose
Dose not stated · injection · 84 ± 5 daysAs given in this study (human).
Source sentences
Summary
There was no change in weight-adjusted TEE (p = 0.20), resting metabolic rate (p = 0.51), or physical activity energy expenditure (p = 0.38) and no change in the unadjusted thermic effect of a meal (p = 0.37).
1 context sentence(design, population, supporting numbers)
Summary · context
After exclusion criteria application, 28 subjects entered into the study and 18 subjects (12 female, 6 male) completed the study, which consisted of 6 visits over 14 weeks and injection of exenatide for an average of 84 ± 5 days.
Report a problemFND-2273503504
05HumanNon-randomized trialEfficacy outcome
In obese participants, resting metabolic rate did not change during exenatide administration.
In plain wordsIn obese participants, resting energy use did not change during exenatide treatment.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeResting metabolic rate
Study
n = 18
Outcome group
Energy expenditure and thermogenesis · Metabolic and weight
Studied dose
Dose not stated · injection · 84 ± 5 daysAs given in this study (human).
Source sentences
Summary
There was no change in weight-adjusted TEE (p = 0.20), resting metabolic rate (p = 0.51), or physical activity energy expenditure (p = 0.38) and no change in the unadjusted thermic effect of a meal (p = 0.37).
1 context sentence(design, population, supporting numbers)
Summary · context
After exclusion criteria application, 28 subjects entered into the study and 18 subjects (12 female, 6 male) completed the study, which consisted of 6 visits over 14 weeks and injection of exenatide for an average of 84 ± 5 days.
Report a problemFND-2273503505
06HumanNon-randomized trialEfficacy outcome
In obese participants, physical activity energy expenditure did not change during exenatide administration.
In plain wordsIn obese participants, energy use from physical activity did not change during exenatide treatment.
Peptide
Exenatide (exendin-4)
Outcome
No significant changePhysical activity energy expenditure
Study
n = 18
Outcome group
Energy expenditure and thermogenesis · Metabolic and weight
Studied dose
Dose not stated · injection · 84 ± 5 daysAs given in this study (human).
Source sentences
Summary
There was no change in weight-adjusted TEE (p = 0.20), resting metabolic rate (p = 0.51), or physical activity energy expenditure (p = 0.38) and no change in the unadjusted thermic effect of a meal (p = 0.37).
1 context sentence(design, population, supporting numbers)
Summary · context
After exclusion criteria application, 28 subjects entered into the study and 18 subjects (12 female, 6 male) completed the study, which consisted of 6 visits over 14 weeks and injection of exenatide for an average of 84 ± 5 days.
Report a problemFND-2273503506
07HumanNon-randomized trialEfficacy outcome
In obese participants, the unadjusted thermic effect of a meal did not change during exenatide administration.
In plain wordsIn obese participants, energy use after a meal did not change during exenatide treatment.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeThermic effect of a meal
Study
n = 18
Outcome group
Energy expenditure and thermogenesis · Metabolic and weight
Studied dose
Dose not stated · injection · 84 ± 5 daysAs given in this study (human).
Source sentences
Summary
There was no change in weight-adjusted TEE (p = 0.20), resting metabolic rate (p = 0.51), or physical activity energy expenditure (p = 0.38) and no change in the unadjusted thermic effect of a meal (p = 0.37).
1 context sentence(design, population, supporting numbers)
Summary · context
After exclusion criteria application, 28 subjects entered into the study and 18 subjects (12 female, 6 male) completed the study, which consisted of 6 visits over 14 weeks and injection of exenatide for an average of 84 ± 5 days.
Report a problemFND-2273503507
08HumanNon-randomized trialMechanism
In obese participants, the authors attributed exenatide-associated weight loss to decreased energy intake by deduction.
In plain wordsIn obese participants, the authors inferred that reduced food energy caused the weight loss during exenatide treatment.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseDeduced energy intake
Study
n = 18
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
Dose not stated · injection · 84 ± 5 daysAs given in this study (human).
Source sentences
Summary
The significant weight loss because of exenatide administration was thus the result of decreasing energy intake.
2 context sentences(design, population, supporting numbers)
Summary · context
The aim of the study was to measure the change in total energy expenditure (TEE) and body composition during exenatide administration and by deduction the relative contributions of energy expenditure and energy intake to exenatide-induced weight loss.
Summary · context
After exclusion criteria application, 28 subjects entered into the study and 18 subjects (12 female, 6 male) completed the study, which consisted of 6 visits over 14 weeks and injection of exenatide for an average of 84 ± 5 days.
Report a problemFND-2273503508

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4Results postedNCT00623545

Bioenergetic Alterations After Exenatide Administration

University of Wisconsin, Madisonn = 28Jan 2008 to Apr 2010

Healthy

Trial page ClinicalTrials.govUpdated 9 Jan 2015

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.